Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 1813
TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341292(US9765070, Example 9 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 0.5nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341277(US9765070, Example 5 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 1nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341191(US9765070, Example 2 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 2.30nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341295(US9765070, Example 12 | 7-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 3.10nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341318(US9765070, Example 35 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 3.20nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341318(US9765070, Example 35 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 3.60nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341318(US9765070, Example 35 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 4nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341318(US9765070, Example 35 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 4.30nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341292(US9765070, Example 9 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 4.80nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341295(US9765070, Example 12 | 7-({2-[4-(5-Chloro-2-cyano...)
Affinity DataIC50: 4.90nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341294(US9765070, Example 11 | Ethyl 7-({2-[4-(5-chloro-2...)
Affinity DataIC50: 5nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341269(US9765070, Example 3 | 7-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 6.60nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341293(US9765070, Example 10 | Ethyl 6-({2-[4-(5-chloro-2...)
Affinity DataIC50: 7nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341277(US9765070, Example 5 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 7.10nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341304(US9765070, Example 21 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 8nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341305(US9765070, Example 22 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 8.30nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341311(US9765070, Example 28 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 8.80nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341312(US9765070, Example 29 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 11nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341324(US9765070, Example 41 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 11nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341299(US9765070, Example 16 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 11nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341289(US9765070, Example 6 | 6-({[4-(5-Chloro-2-cyanophe...)
Affinity DataIC50: 11nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341309(US9765070, Example 26 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 12nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341290(US9765070, Example 7 | 6-[(2-{4-[5-Chloro-2-(diflu...)
Affinity DataIC50: 12nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341311(US9765070, Example 28 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 12nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341306(US9765070, Example 23 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 13nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341296(US9765070, Example 13 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 13nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341269(US9765070, Example 3 | 7-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 13nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341320(US9765070, Example 37 | 2-[5-Chloro-4-(5-chloro-2-...)
Affinity DataIC50: 15nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341312(US9765070, Example 29 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 16nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341296(US9765070, Example 13 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 16nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341307(US9765070, Example 24 | N-(3-Butyl[1,2,4]triazolo[...)
Affinity DataIC50: 16nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341191(US9765070, Example 2 | 6-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 16nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341317(US9765070, Example 34 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 17nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341299(US9765070, Example 16 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 17nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341308(US9765070, Example 25 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 20nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341294(US9765070, Example 11 | Ethyl 7-({2-[4-(5-chloro-2...)
Affinity DataIC50: 20nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341304(US9765070, Example 21 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 21nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341317(US9765070, Example 34 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 21nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341303(US9765070, Example 20 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 23nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341308(US9765070, Example 25 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 23nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341300(US9765070, Example 17 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 24nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341309(US9765070, Example 26 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 24nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341302(US9765070, Example 19 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 25nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341324(US9765070, Example 41 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 26nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341305(US9765070, Example 22 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 28nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341320(US9765070, Example 37 | 2-[5-Chloro-4-(5-chloro-2-...)
Affinity DataIC50: 29nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341320(US9765070, Example 37 | 2-[5-Chloro-4-(5-chloro-2-...)
Affinity DataIC50: 29nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341297(US9765070, Example 14 | 2-[5-Chloro-4-(5-chloro-2-...)
Affinity DataIC50: 31nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341298(US9765070, Example 15 | 2-[4-(5-Chloro-2-cyanophen...)
Affinity DataIC50: 31nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM341190(US9765070, Example 1 | 2-({2-[4-(5-Chloro-2-cyanop...)
Affinity DataIC50: 32nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/29/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: